Serine/threonine kinase 33 (STK33), a member of the calcium/calmodulin-dependent kinase (CAMK), plays vital roles in a wide spectrum of cell processes. The present study was designed to investigate whether STK33 expressed in the mammalian 
| INTRODUCTION
Hearing loss is regarded as a very common sensory disorder in humans all over the world, which seriously affects the quality of human life. In most cases, hearing loss is mainly attributable to hair cell (HC) damage caused by ototoxic drugs, of which aminoglycoside antibiotics, including kanamycin, amikacin, neomycin and gentamicin, are such a typical kind of drugs, with the potential to elicit toxic reactions to structures of the inner ear. 1, 2 Although those drugs are widely used to treat gram-negative bacterial infections, the ototoxic side effects have a great limitation in clinical use. Therefore, it is indispensable to better understand the underlying mechanism of aminoglycosides-induced ototoxicity, which may, in turn, conduce to developing more effective therapies.
Serine/threonine kinase 33 (STK33) gene, which is identified in human chromosome 11 and mouse chromosome 7, encodes a serine/threonine kinase. 3, 4 STK33 belongs to a member of the calcium/ calmodulin-dependent kinase (CAMK), 5, 6 which is mainly existed in testis, certain brain regions and embryonic organs such as brain, heart and spinal cord in human and mouse and is likely to participate in spermatogenesis and organ ontogenesis. 7, 8 Studies show that STK33 is co-localized with the intermediate filament protein vimentin in tanycytes of mouse, rat and hamster, 9 which is involved in the dynamic changes of the intermediate filament cytoskeleton assembly/disassembly, and regulates the cell structure as well as a few important functions through the specific phosphorylation of vimentin. 10, 11 It is well known that apoptosis caused by STK33 suppression is mediated by the mitochondrial pathway, PI3K/AKT cascade or the mitogen-activated protein kinases (MAPKs)-signalling pathway. 6 It has been documented that MAPKs, which are composed of a serine/threonine protein kinases, represent the classical signal transduction pathways. 12, 13 Extracellular signal-regulated kinase 1/2 (ERK1/ 2), one of the members of the MAPK family, is able to mediate many physiological and pathological processes, such as cell proliferation, protein synthesis, cell survival, differentiation, migration and apoptosis. [14] [15] [16] [17] Previous studies have shown that activated ERK1/2 is present in both the cytoplasm and the nucleus, 18 whereas inhibiting (MEK1/2) activation significantly reduces inner hair cells (IHCs) death caused by neomycin treatment, suggesting that ERK activation in supporting cells might promote HC death. 15, 18 Moreover, ERK1/2 inhibition in cochlear explants causes a loss of outer hair cells (OHCs). 18, 19 Of note, STK33-retarded apoptosis is possibly linked to ERK1/2 pathway activation relevant to the accumulation of reactive oxygen species (ROSs). 13 Available data have shown that the accumulation of ROSs is enhanced in HC after aminoglycoside exposure 20 and the diverse antioxidants partially alleviated the aminoglycoside ototoxicity both in vitro and in vivo, suggesting a causal relationship between ROS production and HC death. 20 Actually, ROS plays a crucial role in the promotion of apoptosis by interfering mitochondrial permeability, release of cytochrome c and caspases. 21, 22 Thus, the accumulation of ROS is the primary molecular events in the process of HC death by activating multiple apoptotic pathways underpinning the ototoxicity of aminoglycosides. 
| Cochlea dissection and culture
CBA mice at P4, P15, P30 and P60 were decapitated after anaesthesia, and the cochleae were carefully dissected out. The spiral ligament, stria vascularis and tectorial membrane were threw away, and then, basilar membranes were stuck to glass coverslips pre-treated with Cell-Tek (BD Biosciences, Franklin Lakes, NJ, USA). Finally, they were subjected to immunofluorescent staining analysis. The cochlear explants of P3-P5 for primary culture were treated with or without 3 mmol/L gentamicin for 24 hour and, then, underwent immunofluorescent staining and western blotting analysis. | 5287 subcutaneous tissue at the vertex, and reference and ground electrodes were, respectively, placed subcutaneously at ipsilateral ear and thigh.
| Auditory brainstem response (ABR) test
Sound stimuli were presented to the left ear through a metal loudspeaker in the external auditory meatus. Auditory brainstem response waveforms were recorded in 10-dB intervals down from the maximum amplitude until no waveform could be visualized.
| Frozen section
Tissues from CBA mice were dissected after anaesthesia and fixed with 4% paraformaldehyde (PFA) in PBS at 4°C overnight. Then, they were decalcified and then dehydrated by successive 15%, 20% and 30% sucrose in 1× PBS. They were embedded in OCT compound (TissueTek, Sakura Finetek, Torrance, USA) and sliced into the thickness of 7-μm sections performed with a cryostat (Leica CM 1850, Nussloch, Germany).
| Immunofluorescence staining
The samples were fixed with 4% PFA in PBS for 1 hour, permeabilized with 1% Triton X-100 in PBS for 30 minutes and then blocked with 5% bovine serum albumin, 0.1% Triton X-100 and 0.02% sodium azide in PBS (PBT-1) for 1 hour. Then, they were incubated in PBT-1 overnight 
| Cell viability
Cell Counting Kit-8 (CCK8) was used to assess the cell viability. House 
| Statistical analyses
Data were presented as mean ± SD. T test was applied for comparisons between two groups, and one-way ANOVA was used to compare more than two groups. P < 0.05 was considered statistically significant.
| RESULTS

| STK33 is expressed in the cochlea and HEI-OC1 cells
Hair cells were marked by myosin 7a which was usually used as HCs markers. 27 As shown in Figure 1B At P15, STK33 expression was found in OHCs and IHCs ( Figure 1F ).
From P30, STK33 was highly expressed in OHCs and IHCs (Figure 1F) . These results suggested that STK33 was expressed in a specific manner in post-natal mouse cochlea.
| STK33 expression in cochlear HCs is decreased after gentamicin treatment and mitochondrial apoptosis is activated
To explore whether STK33 expression makes a difference in cochlear HCs after gentamicin exposure, CBA mice were chose to subcutaneously inject gentamicin (200 mg/kg) from P7 to P14. The hearing of mice at 5-6 weeks was examined by ABR test. The results showed that the ABR threshold shifts of gentamicin-treated mice were increased compared to that of the control ones (Figure 2A ), 
| STK33 expression is reduced by U0126 treatment which inhibits p-ERK1/2 expression in cochlear HCs and HEI-OC1 cells after gentamicin stimulus
We found that the expression of p-ERK1/2 was significantly 
| NAC treatment successfully rescues cell apoptosis induced by STK33 down-regulation in cochlear HCs and HEI-OC1 cells after gentamicin stimulus
It is reported that ROS is involved in aminoglycoside-induced HC damage. 2, 23, 28 The intracellular ROS level was increased after gentamicin treatment by DCFH-DA staining compared with the untreated control in primary culture of cochlear HCs, but NAC inhibited the intracellular ROS level after gentamicin damage ( Figure 7A ).
As shown in Figure 7B ,C, the expression levels of Bax and cleaved caspase-3 were significantly reduced in pre-treatment of NAC cotreatment with gentamicin group compared with the gentamicin treatment group by western blotting. These results suggested that the mitochondrial apoptosis was inhibited by NAC treatment after gentamicin damage in cochlear HCs.
To determine whether the up-regulation of ROS levels conduced to the increase in sensitivity exposed to gentamicin after 14, 15 We found that in cochlear HCs, cochlear explants and HEI-OC1 cells, the expression of p-ERK1/ 2 was markedly increased after gentamicin insult, suggesting that MAPKs pathway, especially ERK pathway, is truly activated in gentamicin-induced HC apoptosis.
As STK33 suppression has been reported to induce cell apoptosis through MAPK pathway, we subsequently explored the effects of STK33 on MAPK pathway in HCs after gentamicin treatment. In the present study, we found that knockdown of STK33 only significantly inhibited STK33 expression but failed to change the p-ERK1/2 expression in HEI-OC1 cells after gentamicin treatment, whereas U0126 treatment, a MEK1/2 inhibitor, not only inhibited p-ERK1/2 expression but also suppressed STK33 expression. The same phenomenon was also found in primary culture of cochlear HCs after gentamicin exposure. These results indicate that STK33 might be regulated by ERK1/2, and appear in the downstream of ERK1/2, which is consistent with our previous study in tumour cells. 13 As ROS accumulation is generally related to aminoglycosideinduced HC apoptosis 33, 34 and MAPKs can be activated by ROS, 35 we thus assessed the ROS levels in HCs. In this work, F I G U R E 7 NAC Treatment Successfully Rescues Cell Apoptosis Induced by STK33 Down-Regulation in Cochlear HCs and HEI-OC1 Cells After Gentamicin Co-Stimulus. Hair cells (HCs) and transfection of siRNA-STK33 HEI-OC1 cells were pre-incubated with 2 mmol/L NAC for 2 h, followed by treating with 3 mmol/L gentamicin for 24 h. A, The intracellular ROS level was increased after gentamicin treatment by DCFH-DA staining compared to the untreated control. But the intracellular ROS level was decreased by NAC treatment after gentamicin damage in cochlear HCs by DCFH-DA staining. Scale bars = 30 μm. B-C, Western blotting results demonstrated that the expression levels of Bax and cleaved caspase-3 were decreased by NAC co-treatment with gentamicin compared to the gentamicin treatment in cochlear HCs. *P < 0.05, n = 3. D-F, The ROS levels were increased in HEI-OC1 cells transfected of siRNA-STK33 compared to transfected of siRNA-control ones after gentamicin treatment by DCFH-DA staining and flow cytometry, but NAC had the opposite role in the ROS levels. **P < 0.01, ## P < 0.01, n = 3. Scale bars = 50 μm. G-H, Western blotting results demonstrated that the expression levels of Bax and cleaved caspase-3
were significantly decreased in HEI-OC1 cells transfection of siRNA-STK33 in combination with NAC pre-treatment after gentamicin treatment compared to transfection of siRNA-STK33. *P < 0.05, n = 3. HEI-OC1, House Ear Institute-Organ of Corti 1; NAC, N-acetyl-L-cysteine; ROS, reactive oxygen species; STK33, serine/threonine kinase 33
we found that ROS level was dramatically increased in cochlear HCs after gentamicin exposure, which is consistent with other researches. 36 We also found that after gentamicin treatment, the ROS level was significantly increased in HEI-OC1 cells with STK33 knockdown, which indicates that STK33 knockdown might increase the cellular ROS level to induce HC apoptosis. N-acetyl-L-cysteine, which is an important precursor to many antioxidants, plays a key role in attenuating oxidative stress. In the current study, treatment with the ROS scavenger NAC rescued the increased mitochondrial dysfunction and apoptosis in HEI-OC1 cells caused by STK33 down-regulation after gentamicin injury.
Together, STK33 knockdown leads to elevated ROS levels, which further contribute to apoptosis in HEI-OC1 cells after gentamicin injury.
In conclusion, the findings from this work indicate that STK33 decreases the sensitivity to the apoptosis dependent on mitochondrial apoptotic pathway by regulating ROS generation after gentamicin treatment, which provides a new potential target for protection from the aminoglycoside-induced ototoxicity. The exact mechanism(s) by which STK33 regulates the gentamicininduced impairment of inner ear of mice needs to be investigated further.
